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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To determine whether interval brain imaging (performing brain imaging at regular intervals) compared with brain imaging upon
clinical indication (performing brain imaging upon the development of new or worsening symptoms) improves outcomes associated
with cerebral glioma.
To appraise critically and summarise current evidence on the costs and cost-effectiveness of interval brain imaging compared with
symptomatic imaging.
B A C K G R O U N D
Description of the condition
Brain and other central nervous system (CNS) tumours are less
common than many other cancers, accounting for around 1.9%
of new cancer diagnoses annually; however, they are associated
with a higher proportion of cancer deaths, approximately 2.3%
or 189,382 deaths worldwide in 2012 (GLOBOCAN 2012).
Gliomas are brain tumours that arise from glial cells, usually oligo-
dendrocytes and astrocytes. They occur at an annual incidence of
four to 11 people per 100,000 and are more frequent in high-in-
come, industrialised countries (Ohgaki 2009). Gliomas are graded
1 to 4 by the World Health Organization (WHO), according to
their potential to turn cancerous. The 2007 WHO classification
system (Louis 2007), used in completed clinical studies since 2007,
graded gliomas based onhistological characteristics only.However,
in the 2016 WHO classification system, to be used in future stud-
ies, grading depends on both histological and molecular features,
for example, isocitrate dehydrogenase (IDH) status, chromosome
1p 19q, and other genetic parameters (Louis 2016). Using the
2007 WHO classification, gliomas graded 1 and 2 have low po-
tential to turn cancerous and are referred to as low-grade gliomas
(LGGs); these include pilocytic astrocytomas (grade 1), diffuse
astrocytomas, oligodendrogliomas and mixed oligoastrocytomas
(grade 2). High-grade gliomas (HGGs) include anaplastic astrocy-
tomas, anaplastic oligodendrogliomas (grade 3) and glioblastomas
(grade 4).
Grades correspond to prognosis. Grade 1 has a good prognosis and
can often be cured with surgery alone, whereas grade 4 has a poor
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prognosis, and can be rapidly fatal (Louis 2007). Thus, tumour
grade is a key factor in deciding how to treat gliomas. It also plays
a role in determining the timing and frequency of radiographic
follow-up.
Description of the intervention
Brain imaging by magnetic resonance imaging (MRI), or comput-
erised tomography (CT), is key to the diagnosis of a glioma. MRI
is the preferred technique as it has superior soft tissue resolution
and gives a better definition of tumour extent (NCCN 2018; NCI
2017; NICE 2006). However, these imaging techniques are less
useful in distinguishing the type of tumour and grade, or differ-
entiating tumours from inflammatory or ischaemic lesions (e.g.
following a stroke or radiation). Other imaging techniques, such
as magnetic resonance (MR) spectroscopy, MR perfusion imag-
ing, single photon emission computed tomography (SPECT) and
positron emission photometry (PET), can be used to provide ad-
ditional information prior to surgery to improve the accuracy of
histopathological examination (NCCN 2018; NICE 2018).
In addition to diagnosis, brain imaging is an integral part of man-
agement and follow-up of glioma and informs treatment decisions
in the period immediately after diagnosis. After surgery, MRI has
been shown to more accurately identify the extent of residual tu-
mour than the neurosurgeon’s estimation (Albert 1994). Imaging
is also used to assess the tumour’s response among people actively
receiving treatment and, in clinical studies of glioma treatment,
imaging before the start of adjuvant treatment is common practice
(e.g.Malmström 2017;Wick 2012). In a study of bevacizumab for
glioblastoma, performing a follow-up MRI from as early as four
weeks after starting treatment has been reported to be an accurate
predictor of both treatment response and survival (Field 2017).
Outside the immediate treatment period, people with glioma
might also be offered imaging at regular intervals. ’Interval imag-
ing’ is when a clinician submits a request for imaging at a defined
time point in the future to monitor the tumour. It is not known
at that specific time point in the future whether the person af-
fected will be less symptomatic, the same (i.e. stable), or be more
symptomatic at the time of the scan. The imaging is not, there-
fore, planned based on a deterioration of the person’s symptoms.
An alternative approach to interval imaging would be to arrange
a scan when a person notes deterioration in their symptoms, that
is, symptomatic imaging.
There are several scenarios inwhich interval imaging is used among
people with a glioma. Before surgical treatment, among those with
a suspected LGG, interval imaging might be performed to en-
sure that the actual growth of the tumour is not faster than that
expected from the anticipated grade. It might also be considered
for lesions with radiological features of a very low-grade tumour
that do not necessitate immediate treatment, for example, an optic
pathway glioma (NICE 2018). After treatment, interval imaging
is usually performed for both LGGs and HGGs to check for any
new tumour growth and to determine whether treatment has been
successful at halting growth. TheNational Comprehensive Cancer
Network (NCCN) recommends MRI follow-up of LGGs every
three to six months for five years, then at least annually thereafter
(NCCN 2018). For glioblastoma, an MRI two to six weeks after
radiotherapy, then every two to four months for three years, then
every six months indefinitely, is recommended (NCCN 2018).
Possible imaging intervals in National Institute for Health and
Clinical Excellence (NICE), guidance are slightly longer (e.g. for
glioblastoma the suggested intervals are three to six months up to
two years after treatment, then six to 12 months up to three years,
then annually indefinitely (Table 1)). In general, though, for both
LGGs and HGGs, interval duration increases over time from di-
agnosis and treatment. SPECT and PET can also be helpful in the
post-treatment scenario to distinguish between tumour recurrence
and radiation necrosis (NCCN 2018; NCI 2017).
Why it is important to do this review
To our knowledge, there are no existing systematic reviews of this
topic. It is not known whether interval brain imaging leads to im-
proved survival among people with glioma compared with symp-
tomatic imaging. In addition, whilst clinical guidelines recom-
mend routine MRI follow-up or active monitoring, the optimal
frequency of routine active monitoring has not been established.
In existing clinical practice guidelines, it is recommended that
the frequency of routine active monitoring decreases with time
(NICE 2018; NCCN 2018; SEOM 2017); however, as the risk
of LGG recurrence is lower initially and increases with time, fre-
quent imaging early on in the course of the disease, particularly in
people with LGG, might be unnecessary. In addition, diagnostic
uncertainties raised by brain imaging performed within the first
three to six months due to treatment, such as tumour progres-
sion versus pseudo-progression, can increase patient and clinician
anxiety during this active monitoring period, and negatively affect
quality of life. Brain imaging is costly, both for the health system
and the individual, and performing it routinely might not always
be cost-effective or in an individual’s best interest, particularly if
the result of imaging is unlikely to change management. The aim
of this review, therefore, is to systematically evaluate the evidence
on interval imaging versus imaging upon clinical indication, to
inform clinical practice guidelines and research agendas.
O B J E C T I V E S
To determine whether interval brain imaging (performing brain
imaging at regular intervals) compared with brain imaging upon
clinical indication (performing brain imaging upon the develop-
ment of new or worsening symptoms) improves outcomes associ-
ated with cerebral glioma.
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To appraise critically and summarise current evidence on the costs
and cost-effectiveness of interval brain imaging compared with
symptomatic imaging.
M E T H O D S
Criteria for considering studies for this review
Types of studies
For studies on the effectiveness of brain imaging strategies, we will
include randomised controlled trials (RCTs) and non-randomised
controlled trials (NRCTs). If we do not find any RCTs or NRCTs,
we will include controlled before-after studies (CBAS) with con-
current comparison groups.
Full economic evaluations (cost-effectiveness analyses, cost-utility
analyses and cost-benefit analyses), conducted alongside any study
design and any model-based economic evaluations.
Types of participants
Adultswith a histologically confirmeddiagnosis of cerebral glioma.
Types of interventions
Pre- or post-treatment brain imaging, including MRI and other
types of imaging, performed at regular intervals (interval imaging)
compared with pre- or post-treatment brain imaging performed
upon the development of new or worsening symptoms (symp-
tomatic imaging).
Types of outcome measures
Primary outcomes
• Overall survival (time from randomisation to death)
Secondary outcomes
• Progression-free survival (time from randomisation to
disease progression)
• Health-related quality of life measured by a standardised
instrument, such as the European Organisation for Research and
Treatment of Cancer (EORTC) QLQ-C30 or QLQ-BN20
(specific for brain cancer), or the Functional Assessment of
Cancer Therapy scale (FACT)-G (general) or FACT-Br (specific
for brain cancer)
• Anxiety, measured by a standardised instrument, such as the
Hospital Anxiety and Depression Scale (HADS)
• Depression, measured by a standardised instrument, such as
HADS and the Beck Depression Inventory (BDI)
• Economic data (cost, cost-effectiveness, cost-utility and
cost-benefits)
Search methods for identification of studies
Electronic searches
• For studies on effectiveness we will search the following
databases:
◦ Cochrane Central Register of Controlled Trials
(CENTRAL), in the Cochrane Library;
◦ MEDLINE Ovid (from 1946 onwards);
◦ Embase Ovid (from 1980 onwards);
• For economic evidence we will search:
◦ MEDLINE Ovid (from 2015);
◦ Embase Ovid (from 2015);
◦ NHS Economic evaluation database (EED) to
December 2014
The EED database will be searched up to the end of December
2014 (when the last records were added to that database) and
MEDLINE and Embase from 1st January 2015, as NHS EED
already included comprehensive searches of these databases prior
to 2015. We will also consider relevant grey literature, such as
health technology assessments, reports and working papers, for
inclusion.
Please refer to Appendix 1 for draft MEDLINE search strategies.
We will not apply language restrictions to any of the searches.
Searching other resources
We will search the following for ongoing studies:
• ClinicalTrials.gov (clinicaltrials.gov/)
• International Clinical Trials Registry Platform ( ICTRP) (
apps.who.int/trialsearch/)
If we identify any ongoing studies that have not been published
through these searches, wewill approach the principal investigators
to ask for an update on the study status and any relevant data if
available.
We will use the related articles feature of PubMed and handsearch
the reference lists of included studies to identify newly published
articles and additional studies of relevance.
Data collection and analysis
Selection of studies
3Interval brain imaging for adults with cerebral glioma (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
For the results of the search for studies on effectiveness, the
Cochrane Gynaecological, Neuro-oncology and Orphan Cancer
(CGNOC) Information Specialist will download all titles and ab-
stracts retrieved by electronic searching to Endnote® and remove
duplicates. Two review authors (Theresa Lawrie (TL) and one
other), will independently screen the remaining records and ex-
clude studies that clearly do not meet the eligibility criteria. For
potentially eligible records, we will obtain copies of the full texts
and two review authors (TL and Gerard Thompson (GT)), will
independently assess them for eligibility. The two review authors
concerned will resolve any disagreements by discussion with each
other and, if necessary, they will consult at least one other review
author. We will use Covidence to facilitate this study selection
process and will document reasons for exclusion accordingly.
For the results of searches for economic evidence, two reviewers
(LukeVale (LV) andAshleighKernohan (AK)), will independently
screen for, identify and classify eligible studies as above.
Data extraction and management
Data from included intervention studies will be extracted inde-
pendently by two review authors (TL and GT), to a pre-designed
data extraction form to include the following.
• Author contact details
• Country
• Setting
• Dates of participant accrual
• Funding source
• Inclusion and exclusion criteria
• Study design
• Study population and baseline characteristics:
◦ number of participants enrolled;
◦ number of participants analysed;
◦ age of participants;
◦ gender of participants;
◦ type of glioma (low grade or high grade; tumour size,
molecular markers);
◦ type of glioma treatment (surgery; radiotherapy;
chemotherapy).
• Intervention details:
◦ type of intervention (interval imaging), including
whether it occurs pre-treatment or post-treatment, the interval
period, and the type of scan (e.g. MRI);
◦ type of comparator (symptomatic imaging), including
indications for imaging, information on the timing of the
imaging (e.g. median time to first scan post-treatment), and the
type of scan.
• ’Risk of bias’ assessment (see below)
• Duration of follow-up
• Primary outcome(s) of the study
• Review outcomes
◦ For time-to-event outcomes (overall and progression-
free survival), we will extract the hazard ratio (HR) with its 95%
confidence interval (CI) for time points as reported by the study
authors. We will note the definition of and procedure used to
identify progression. Where reported, we will also extract
dichotomous data for these outcomes at author-specified time
points.
◦ For dichotomous outcomes (e.g. anxiety, depression),
we will extract the number of participants in each treatment arm
that experienced the outcome of interest and the number of
participants assessed.
◦ For continuous outcomes (e.g. quality-of-life scores,
anxiety, depression), we will extract the value and standard
deviation of the outcome of interest and the number of
participants assessed at the relevant time point in each group. We
will also extract change-from-baseline score data where reported
and note the type of scale used.
◦ We will extract adjusted statistics where reported.
◦ Where possible, all data extracted will be those
relevant to an intention-to-treat analysis, in which participants
were analysed in the groups to which they were assigned.
◦ We will resolve differences between review authors by
discussion or by appeal to a third review author when necessary.
We will develop a data extraction form for economic evaluations
based on the format and guidelines used to produce structured
abstracts of economic evaluations for inclusion in the NHS Eco-
nomic Evaluation Database (NHS EED), adapted to the specific
requirements of this review. In addition to the outcomes described
above, economic evaluation studies will also extract the following
data.
• Type of evaluations
• Sources of effectiveness data
• Cost data
• Sources of cost data
• Sources of outcome valuations
• Analytical approach
Two review authors, LV and AK, will extract the economic out-
comes.
Assessment of risk of bias in included studies
For studies of clinical effects, we will assess the risk of bias using
Cochrane’s tool and the criteria specified in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2017). This
includes assessment of:
• random sequence generation;
• allocation concealment;
• blinding of participants and healthcare providers;
• blinding of outcome assessors;
• incomplete outcome data (more than 20% missing data
considered high risk);
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• selective reporting of outcomes;
• other possible sources of bias, such as lack of a power
calculation, baseline differences in group characteristics.
Two review authors (TL and GT) will assess risk of bias indepen-
dently and will resolve any differences by discussion or by appeal
to a third review author. We will summarise judgements in ’Risk
of bias’ tables along with the characteristics of the included stud-
ies. We will interpret the results of the meta-analyses in light of
the overall ’Risk of bias’ assessment. For more details about the
assessment of risk of bias, see Appendix 2.
We will assess economic evaluation studies for bias in two stages.
The first stage will involve assessing risk of bias from the sources of
the effectiveness data. We will assess economic evaluations carried
out alongside clinical studies using theCochrane ’Risk of bias’ tool,
as described above. If the economic evaluation is model-based, we
will use the ROBIS tool to assess bias in the effectiveness studies
(Whiting 2016). The second stage involves assessing the risk of
bias of the economic evidence (i.e. assessing the overall method-
ological quality). We will use the CHEERS and Evers checklists
to do this. ( hsr.mumc.maastrichtuniversity.nl/consensus-health-
economic-criteria-chec-list), (Husereau 2013; Thielen 2016; Van
Mastrigt 2016; Wijnen 2016).
Measures of treatment effect
• For time-to-event outcomes (e.g. overall survival) we will
extract the hazard ratio (HR) with its 95% CI.
• For continuous outcomes (e.g. quality-of-life scores) we
assume that study authors will use different measurement scales,
therefore, we plan to estimate the standardised mean difference
(SMD) and its 95% CI using the pooled data. However, if the
same measurement scale is used, we will estimate the mean
difference (MD) and its 95% CI. If studies do not report total
values but, instead, report change-from-baseline outcomes, we
will combine these change values with total measurement
outcomes by using the (unstandardised) mean difference method
in Review Manager 5 (RevMan 5), (Review Manager 2014). We
will use subgroups to distinguish between MDs of change scores
and MDs of final values, and pool the subgroups in an overall
analysis (Deeks 2017).
• For dichotomous outcomes, we will calculate the effect size
as a risk ratio (RR) with its 95% CI.
Unit of analysis issues
Two review authors (TL and GT) will review unit of analysis
issues according to Deeks 2017 and will resolve any differences by
discussion. These include reports where:
• groups of individuals are randomised together to the same
intervention (i.e. cluster-randomised studies); or
• there are multiple observations for the same outcome (e.g.
repeated measurements with different scales or at different time-
points, recurring events).
Dealing with missing data
We will not impute missing data. In the event of missing data,
we will write to study authors to request the data and describe
in the characteristics of studies tables how any missing data were
obtained.
Assessment of heterogeneity
We will assess heterogeneity between studies in each meta-analysis
by visual inspection of forest plots, by estimation of the percentage
heterogeneity between studies that cannot be ascribed to sampling
variation (Higgins 2003), by a formal statistical test of the signifi-
cance of the heterogeneity (Deeks 2008), and, where possible, by
subgroup analyses. If there is evidence of substantial heterogeneity,
we will investigate and report the possible reasons for it.
Assessment of reporting biases
If there are 10 or more studies in meta-analyses we will investigate
reporting biases (such as publication bias) using funnel plots. We
will assess funnel plot asymmetry visually. If asymmetry is sug-
gested by a visual assessment, we will perform exploratory analyses
to investigate it (Sterne 2017).
Data synthesis
We will conduct meta-analyses if participants, comparisons and
outcomes are judged to be sufficiently similar to ensure an an-
swer that is clinically meaningful. We will use the random-effects
model with inverse variance weighting for all meta-analyses. If
any studies have multiple intervention groups, we will divide the
‘shared’ comparison group into the number of treatment groups
and comparisons between each treatment group, and treat the split
comparison group as independent comparisons. We will perform
meta-analysis of the results assuming that we find at least two in-
cluded studies that are sufficiently similar for the findings to be
clinically meaningful. When a meta-analysis is not possible due to
the availability of single studies only, we will enter the data from
single studies into RevMan 5 (Review Manager 2014), without
totals, and grade the findings as described below.
We will summarise characteristics and results of included eco-
nomic evaluations using additional tables, supplemented by a nar-
rative summary that will compare and evaluate methods used and
principal results between studies. We will also tabulate unit cost
data, when available. We will report the currency and price year
applicable to measures of costs in each original study, alongside
measures of costs, incremental costs and incremental cost-effec-
tiveness, by study. Where details of currency and price year are
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available in original studies, we will convert measures of costs,
incremental costs and cost-effectiveness to ( latest year) Interna-
tional Dollars value using implicit price deflators for GDP and
GDP Purchasing Power Parities ( eppi.ioe.ac.uk/costconversion/
default.aspx; Shemlit 2011). We will summarise details of the
methodological characteristics of individual included health eco-
nomics studies ‘Characteristics of included studies’ tables. We will
conduct all elements of the economics component of this review
according to current guidance on the use of economics methods in
the preparation and maintenance of Cochrane Reviews (Shemlit
2011).
GRADE, ’Summary of findings’ tables and results
reporting
Based on the methods described in Chapter 11 of the Cochrane
Handbook for Systematic Reviews of Interventions (Schünemann
2017a), we will prepare a ’Summary of findings’ table (see example
Table 2) to present the results of the following outcomes, separately
for LGGs and HGGs.
• Overall survival
• Progression-free survival
• Quality of life
• Anxiety
• Depression
For each assumed risk cited in the tables, we will provide a ratio-
nale, and we will use the GRADE system to rank the quality of the
evidence (Schünemann 2017b). Where the evidence is based on
single studies, or where there is no evidence on a specific outcome,
we will include the outcome in the ’Summary of findings’ tables
and grade or explain accordingly. Two review authors will grade
the evidence together. We will consider downgrading evidence of
a clear effect derived from single studies with small sample sizes
or few events. We will resolve any differences of opinion by dis-
cussion and, if necessary, by involving a third review author. We
will report the results of the meta-analyses in the text based on the
guidance from Cochrane Effective Practice and Organisation of
Care on review results reporting and interpretation (EPOC2015).
For the economic evaluation studies, we will present the following
findings in a table.
• Method of economic evaluation
• Costs
• Outcomes
• Incremental cost-effectiveness ratio
Subgroup analysis and investigation of heterogeneity
We will perform subgroup analysis by the glioma grade (LGG
and HGG) and molecular markers, if possible. We will use formal
tests for subgroup differences to determine whether the effect of
interventions differs according to these subgroups. Depending on
these findings, we will consider whether an overall summary is
meaningful. We will consider factors such as age, gender, type of
treatment, and risk of bias in interpretation of any heterogeneity.
If we identify substantial heterogeneity, we will investigate it in
sensitivity analyses.
Sensitivity analysis
We will perform sensitivity analysis to investigate substantial het-
erogeneity identified in meta-analyses of primary outcomes and
also to evaluate the effect after excluding studies at high risk of
bias, to investigate how study quality affects the certainty of the
findings.
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A D D I T I O N A L T A B L E S
Table 1. National Institute for Health and Clinical Excellence (NICE) guidance on interval imaging
Tumour grade Years after end of treatment
0 to 1 1 to 2 2 to 3 3 to 4 5 to 10 > 10 (for the rest of life)
Grade 1 Scan at 12 months, then:
• consider discharge if no tumour visible on imaging unless completely resected pilocytic astrocytoma
• consider ongoing imaging at increasing intervals for 15 years for completely resected pilocytic astrocytoma
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Table 1. National Institute for Health and Clinical Excellence (NICE) guidance on interval imaging (Continued)
• consider if ongoing imaging is needed at a rate of once every 1 to 3 years for the rest of the person’s life if
the tumour is visible on imaging
Grade II 1p/19q
non-codeleted,
IDH mutated
Scan at
3 months, then
every 6 months
Annually Every 1 to
2 years
Consider ongoing imaging
every 1 to 2 years
Grade II 1p/19q
codeleted
Grade III 1p/
19q
codeleted
Grade II IDH
wildtype
Every 3 to
6 months
Every 6 to
12 months
Annually Consider ongoing imaging
every 1 to 2 years
Grade III 1p/
19q
non-codeleted
Grade IV
(glioblastoma)
From NICE 2018 (p17) Table 3: Possible regular clinical review schedule for people with glioma depending on grade of tumour
Table 2. Summary of findings
Pre-treatment interval imaging compared with pre-treatment imaging on indication for low-grade glioma
Patient or population: people with low-grade glioma
Settings: tertiary care
Intervention: pre-treatment interval imaging
Comparison: pre-treatment imaging on indication
Outcomes Illustrative comparative risks*
(95% CI)
Relative effect
(95% CI)
No of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Assumed risk Corresponding
risk
Imaging on in-
dication
Pre-
treatment inter-
val imaging
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Table 2. Summary of findings (Continued)
Overall survival
(5 years)
Low risk population RR (value) (
(value) to (value)
)
(value)
((value))
(Delete as
appropriate)
⊕©©©
very low
⊕⊕©©
low
⊕⊕⊕©
moderate
⊕⊕⊕⊕
high
[value)per 1000 (value)per 1000
((value) to
(value))
Medium risk population
(value)per 1000 (value)per 1000
((value) to
(value))
Progression-
free survival (5
years)
Low risk population RR (value) (
(value) to (value)
)
(value)
((value))
(Delete as
appropriate)
⊕©©©
very low
⊕⊕©©
low
⊕⊕⊕©
moderate
⊕⊕⊕⊕
high
(value)per 1000 (value)per 1000
((value) to
(value))
Medium risk population
(value)per 1000 (value)per 1000
((value) to
(value))
Post-imaging
QoL score*
The mean (out-
come) ranged
across control
groups from
(value)(measure)
The mean (out-
come) in the in-
tervention
groups was
(value) (lower/
higher)
((value to value
lower/higher))
(value)
((value))
(Delete as
appropriate)
⊕©©©
very low
⊕⊕©©
low
⊕⊕⊕©
moderate
⊕⊕⊕⊕
high
Anxiety* Low risk population RR (value) (
(value) to (value)
)
(value)
((value))
(Delete as
appropriate)
⊕©©©
very low
⊕⊕©©
low
⊕⊕⊕©
moderate
⊕⊕⊕⊕
high
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Table 2. Summary of findings (Continued)
(value)per 1000 (value)per 1000
((value) to
(value))
Medium risk population
(value)per 1000 (value)per 1000
((value) to
(value))
High risk population
(value)per 1000 (value)per 1000
((value) to
(value))
Depression* Low risk population RR (value) (
(value) to (value)
)
(value)
((value))
(Delete as
appropriate)
⊕©©©
very low
⊕⊕©©
low
⊕⊕⊕©
moderate
⊕⊕⊕⊕
high
(value)per 1000 (value)per 1000
((value) to
(value))
Medium risk population
(value)per 1000 (value)per 1000
((value) to
(value))
High risk population
(value)per 1000 (value)per 1000
((value) to
(value))
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk
(and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention
(and its 95% CI).
CI: confidence interval; QoL: quality of life; RR: risk ratio; (other abbreviations, e.g. OR, etc)
GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect,
but there is a possibility that it is substantially different.
Low quality: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low quality: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect
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*It is likely that different measurement time points and scales will be used in different studies. Where this is the case, we will attempt
to synthesise the evidence narratively.
A P P E N D I C E S
Appendix 1. MEDLINE draft search strategy
Draft MEDLINE strategy with RCT filter
1. exp Glioma/
2. (glioma* or astrocytoma* or ependymoma* ganglioglioma* or gliosarcoma* or oligodendroglioma* or glioblastoma* or oligoastro-
cytoma* or GBM*).ti,ab.
3. 1 or 2
4. neuroimaging/
5. exp Magnetic Resonance Imaging/
6. (MRI or MRi or magnetic resonance imag*).ti,ab.
7. (brain* adj5 (imag* or scan*)).ti,ab.
8. Tomography, X-Ray Computed/
9. ((CT or CAT or compute* tomograph*) adj5 (scan* or imag*)).ti,ab.
10. exp Positron-Emission Tomography/
11. (positron-emission tomography* or PET).ti,ab.
12. exp Magnetic Resonance Spectroscopy/
13. (magnetic resonance spectroscop* or MR*).ti,ab.
14. contrast-enhanced computerised tomography or CT.ti,ab.
15. Perfusion Imaging/
16. exp Tomography, Emission-Computed, Single-Photon/
17. SPEC or SPECT.ti,ab.
18. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19. 3 and 18
20. ((inter* or routin* or regular* or frequen* or sequential or continuous* or serial* or recur*or longitudinal* or repeat*) adj5 (scan*
or imag*)).ti,ab.
21. 19 and 20
Key
mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier
ab=abstract
sh=subject heading
ti=title
pt=publication type
Draft MEDLINE strategy with economic filter
1. exp Glioma/
2. (glioma* or astrocytoma* or ependymoma* ganglioglioma* or gliosarcoma* or oligodendroglioma* or glioblastoma* or oligoastro-
cytoma* or GBM*).ti,ab.
3. 1 or 2
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4. neuroimaging/
5. exp Magnetic Resonance Imaging/
6. (MRI or MRi or magnetic resonance imag*).ti,ab.
7. (brain* adj5 (imag* or scan*)).ti,ab.
8. Tomography, X-Ray Computed/
9. ((CT or CAT or compute* tomograph*) adj5 (scan* or imag*)).ti,ab.
10. exp Positron-Emission Tomography/
11. (positron-emission tomography* or PET).ti,ab.
12. exp Magnetic Resonance Spectroscopy/
13. (magnetic resonance spectroscop* or MR*).ti,ab.
14. contrast-enhanced computerised tomography.mp. or CT.ti,ab. [mp=title, abstract, original title, name of substance word, subject
heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique
identifier, synonyms]
15. Perfusion Imaging/
16. exp Tomography, Emission-Computed, Single-Photon/
17. SPEC.mp. or SPECT.ti,ab. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
18. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19. 3 and 18
20. ((inter* or routin* or regular* or frequen* or sequential or continuous* or serial* or recur*or longitudinal* or repeat*) adj5 (scan*
or imag*)).ti,ab.
21. 19 and 20
22. Economics/
23. exp “costs and cost analysis”/
24. Economics, Dental/
25. exp economics, hospital/
26. Economics, Medical/
27. Economics, Nursing/
28. Economics, Pharmaceutical/
29. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
30. (expenditure$ not energy).ti,ab.
31. value for money.ti,ab.
32. budget$.ti,ab.
33. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
34. ((energy or oxygen) adj cost).ti,ab.
35. (metabolic adj cost).ti,ab.
36. ((energy or oxygen) adj expenditure).ti,ab.
37. 34 or 35 or 36
38. 33 not 37
39. letter.pt.
40. editorial.pt.
41. historical article.pt.
42. 39 or 40 or 41
43. 38 not 42
44. 21 and 43
Key
mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier
ab=abstract
sh=subject heading
ti=title
pt=publication type
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Appendix 2. Assessment of risk of bias
For randomised controlled trials
We will assess the risk of bias according to the following criteria:
(1) Random sequence generation
• Low risk of bias e.g. participants assigned to treatments on basis of a computer-generated random sequence or a table of random
numbers
• High risk of bias e.g. participants assigned to treatments on basis of date of birth, clinic ID-number or surname, or no attempt
to randomise participants
• Unclear risk of bias e.g. not reported, information not available
(2) Allocation concealment
• Low risk of bias e.g. where the allocation sequence could not be foretold
• High risk of bias e.g. allocation sequence could be foretold by participants, investigators or treatment providers
• Unclear risk of bias e.g. not reported
(3) Blinding of participants and personnel
• Low risk of bias if participants and personnel were adequately blinded
• High risk of bias if participants and/or personnel were not blinded to the intervention that the participant received
• Unclear risk of bias if this was not reported or unclear
(4) Blinding of outcome assessors
• Low risk of bias if outcome assessors were adequately blinded to the intervention that the participant received
• High risk of bias if outcome assessors were not blinded to the intervention that the participant received
• Unclear risk of bias if this was not reported or unclear
(5) Incomplete outcome data
We will record the proportion of participants whose outcomes were not reported at the end of the study. We will code a satisfactory
level of loss to follow-up for each outcome as:
• low risk of bias, if fewer than 20% of participants were lost to follow-up and reasons for loss to follow-up were similar in both
treatment arms
• High risk of bias, if more than 20% of participants were lost to follow-up or reasons for loss to follow-up differed between
treatment arms
• Unclear risk of bias if loss to follow-up was not reported
(6) Selective reporting of outcomes
• Low risk of bias e.g. review reports all outcomes specified in the protocol
• High risk of bias e.g. It is suspected that outcomes have been selectively reported
• Unclear risk of bias e.g. It is unclear whether outcomes had been selectively reported
(7) Other bias
• Low risk of bias, i.e.no other source of bias suspected and the study appears to be methodologically sound
• High risk of bias: we suspect that the study was prone to an additional bias
• Unclear risk of bias: we are uncertain whether an additional bias may have been present
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For non-randomised controlled trials and controlled before-after studies
We will assess the risk of bias in accordance with four criteria concerning sample selection comparability of treatment groups:
(1) Relevant details of criteria for assignment of patients to treatments
• Low risk of bias, e.g. yes, details provided
• High risk of bias, e.g. no details provided
• Unclear risk of bias, e.g. details unclear
(2) Representative group of people who received the experimental intervention
• Low risk of bias, if representative of participants with low and/or high grade gliomas who receive interval brain imaging to assess
their condition
• High risk of bias, if groups of participants were selected (non-consecutive)
• Unclear, if selection of the group was not described
(3) Representative group of people who received the comparison intervention
• Low risk of bias, if drawn from the same population as the experimental group
• High risk of bias, if drawn from a different source
• Unclear risk of bias, if selection of group not described
(4) Baseline differences between groups controlled for, in particular with reference to age, gender, grade of glioma and
glioma treatment
• Low risk of bias, if at least three of these characteristics were reported
• High risk of bias, if the groups differed in these baseline characteristics and differences were not controlled for
• Unclear risk of bias, if fewer than three of these characteristics were reported even if there were no other differences between the
groups, and other characteristics were controlled for
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